糖尿病脑血管病血浆GMP-140变化的研究

A STUDY ON THE CHANGES IN GMP-140 IN PATIENTS WITH DIABETES AND CEREBRAL VASCULAR DISEASES

为探讨糖尿病脑血管病血浆GMP 14 0的变化及其意义 ,采用放免法和常规计数法分别测定 13例糖尿病合并脑梗死患者血浆颗粒膜蛋白 (GMP 14 0 )和血小板数量 ,并以单纯糖尿病、单纯脑梗死及正常人作对照。结果显示 ,糖尿病合并脑梗死患者与各对照组间的血小板计数差异无显著性意义 (P >0 0 5 ) ;GMP 14 0水平则显著高于糖尿病组及正常人 (P <0 0 1) ,与单纯脑梗死组比较差异无显著性意义。提示血浆GMP 14

To investigate the change in GMP 140 and its significance in patients with diabetes accompanied with cerebral infarction. Plasma GMP 140 levels were assayed by radilimmunoassay in diabetes accompanied with cerebral infarction, controlled diabetes, cerebral infarction patients and normal controls, respectively. The results showed the GMP 140 levels were significantly higher in patients with diabetes accompanied with cerebral infarction than in patients with diabetes and normal control ( P <0 01), but no differences were observed when compared with those of cerebral infarction patients. There was no difference in platelet counts among four groups ( P >0 05). The results suggested that the level of GMP 140 in plasma might be used as a sensitive and reliable indicator reflecting the degree of platelet activation.